Cisplatin- and gemcitabine-based chemotherapeutics represent a mainstay of cancer therapy for most solid tumors; however, resistance limits their curative potential. Here, we identify RNA polymerase II-associated factor 1 (PAF1) as a common driver of cisplatin and gemcitabine resistance in human cancers (ovarian, lung, and pancreas). Mechanistically, cisplatin- and gemcitabine-resistant cells show enhanced DNA repair, which is inhibited by PAF1 silencing. We demonstrate an increased interaction of PAF1 with RAD52 in resistant cells. Targeting the PAF1 and RAD52 axis combined with cisplatin or gemcitabine strongly diminishes the survival potential of resistant cells. Overall, this study shows clinical evidence that the expression of PAF1 contributes to chemotherapy resistance and worse clinical outcome for lethal cancers.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Rauth, Sanchita; Ganguly, Koelina; Atri, Pranita; Parte, Seema; Nimmakayala, Rama Krishna; Varadharaj, Venkatesh; Nallasamy, Palanisamy; Vengoji, Raghupathy; Ogunleye, Ayoola O.; Lakshmanan, Imayavaramban; Chirravuri, Ramakanth; Bessho, Mika; Cox, Jesse L.; Foster, Jason M.; Talmon, Geoffrey A.; Bessho, Tadayoshi; Ganti, Apar Kishor; Batra, Surinder K.; and Ponnusamy, Moorthy P., "Elevated PAF1-RAD52 Axis Confers Chemoresistance to Human Cancers" (2023). Journal Articles: Biochemistry & Molecular Biology. 158.